clinical trial · NCT05670379
Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant
Vivani Medical, Inc·phase1·completed·n = 24
Overweight and ObesityType2diabetesExenatide ImplantBydureon BCise (exenatide extended release)Semaglutide, 1.0 mg/mL
brief summary
The purpose of this study is to evaluate the safety, tolerability and drug levels of an exenatide implant administered subcutaneously.
started
Dec 20, 2024
primary completion
Aug 21, 2025
completion
Aug 21, 2025
last updated
Sep 23, 2025
official title
A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Exenatide Implant
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol